Polycystic Ovary Syndrome Medical Services in China

Polycystic Ovary Syndrome (PCOS) is a common, complex endocrine-metabolic disorder affecting individuals of reproductive age. It is characterized by chronic anovulation, hyperandrogenism (clinical or biochemical), and polycystic ovarian morphology on ultrasound—though diagnosis requires at least two of these three criteria per the Rotterdam criteria, after excluding other causes of hyperandrogenism and anovulation. PCOS is not merely a gynecological condition but a systemic disorder with profound implications for metabolic, cardiovascular, and psychological health. Its pathogenesis remains incompletely understood but involves a combination of genetic predisposition, insulin resistance, compensatory hyperinsulinemia, and neuroendocrine dysregulation—particularly exaggerated luteinizing hormone (LH) pulsatility and altered gonadotropin-releasing hormone (GnRH) secretion. Insulin resistance drives ovarian theca cell androgen overproduction and impairs follicular maturation, while adipose tissue inflammation and dysbiosis may further amplify hormonal and metabolic dysfunction. Epidemiologically, PCOS affects approximately 6–12% of women globally, with prevalence varying by diagnostic criteria and population—studies in China report rates of 5.6–8.7% among reproductive-age women. Risk factors include family history (first-degree relatives with PCOS or type 2 diabetes), obesity (especially central adiposity), sedentary lifestyle, prenatal androgen exposure, and early menarche. Importantly, PCOS is strongly associated with long-term comorbidities: up to 40% develop prediabetes or type 2 diabetes by age 40; 30–50% have metabolic syndrome; and cardiovascular risk markers—including hypertension, dyslipidemia, and endothelial dysfunction—are significantly elevated. Beyond physiology, PCOS substantially impacts quality of life: menstrual irregularity, hirsutism, acne, alopecia, and infertility contribute to body image distress, anxiety, depression (prevalence 25–40%), and reduced sexual well-being. Social stigma around appearance and fertility challenges often leads to delayed help-seeking and treatment nonadherence. Early diagnosis and individualized, multidisciplinary management—spanning endocrinology, gynecology, nutrition, and mental health—are critical to mitigate both immediate symptoms and lifelong morbidity.

Polycystic Ovary Syndrome (PCOS) is a heterogeneous endocrine-metabolic disorder affecting approximately 6–12% of women of reproductive age worldwide. Characterized by chronic anovulation, hyperandrogenism (clinical or biochemical), and polycystic ovarian morphology on ultrasound—diagnosed using the Rotterdam criteria—PCOS is associated with insulin resistance, obesity, dyslipidemia, increased risk of type 2 diabetes mellitus (T2DM), cardiovascular disease, endometrial hyperplasia, and infertility. Management in the Department of Endocrinology emphasizes individualized, multidisciplinary, and long-term strategies targeting both reproductive and metabolic manifestations.

Conservative treatment forms the cornerstone of PCOS management, particularly for overweight or obese patients (BMI ≥25 kg/m²). Lifestyle modification—including structured dietary intervention, regular physical activity, and behavioral support—is evidence-based first-line therapy. A hypocaloric, low-glycemic-index diet emphasizing whole grains, lean protein, fiber-rich vegetables, and healthy fats improves insulin sensitivity and reduces androgen levels. Supervised aerobic and resistance exercise for ≥150 minutes per week has demonstrated significant reductions in body weight (5–10%), waist circumference, fasting insulin, and free testosterone, while restoring ovulatory function in up to 40% of previously anovulatory women. Cognitive-behavioral therapy (CBT) and digital health platforms are increasingly integrated into Chinese outpatient programs to enhance adherence, address body image concerns, and mitigate anxiety/depression comorbidities prevalent in PCOS.

Pharmacotherapy is initiated based on symptom priority: menstrual irregularity, hirsutism/acne, infertility, or metabolic risk. Combined oral contraceptives (COCs)—containing ethinyl estradiol and a low-androgenic progestin (e.g., drospirenone or norgestimate)—are first-line for cycle regulation, endometrial protection, and androgen suppression. Metformin remains widely used off-label in insulin-resistant PCOS, especially in adolescents and preconception counseling; it improves ovulation rates, reduces hyperinsulinemia, and may lower miscarriage risk. In China, metformin is often prescribed at 500–1500 mg/day, titrated gradually to minimize gastrointestinal side effects. For hyperandrogenism refractory to COCs, spironolactone (50–200 mg/day) is commonly employed as an antiandrogen, though contraception must be strictly enforced due to teratogenic risk. Clomiphene citrate remains the initial ovulation induction agent for infertility; however, letrozole—a selective aromatase inhibitor—is now preferred in many Chinese fertility centers due to superior live birth rates and lower multiple pregnancy risk. GLP-1 receptor agonists (e.g., semaglutide, approved in China for obesity/T2DM) are emerging as adjunctive agents in PCOS with obesity and prediabetes, demonstrating robust weight loss, improved insulin sensitivity, and restoration of menstrual cyclicity in early-phase trials.

Surgical treatment plays a limited but defined role. Laparoscopic ovarian drilling (LOD) is reserved for clomiphene- or letrozole-resistant anovulatory infertility after thorough evaluation of tubal patency and male factor. Performed under general anesthesia, LOD involves diathermy or laser ablation of 3–5 ovarian wedge sites, reducing ovarian stromal volume and local androgen production. It restores spontaneous ovulation in ~70% of responders within 3–6 months, with cumulative pregnancy rates comparable to gonadotropin therapy but without the risks of ovarian hyperstimulation syndrome (OHSS) or multiple gestation. However, LOD carries potential complications including adhesion formation, ovarian failure (rare), and technical variability. In China, LOD is performed in tertiary endocrinology-reproductive centers with standardized protocols and intraoperative laparoscopic ultrasound guidance to optimize precision and safety. It is not indicated for metabolic management or hirsutism alone.

Treatment advantages in China include rapid integration of national clinical guidelines (e.g., the 2023 Chinese Society of Endocrinology PCOS Consensus), widespread access to tiered healthcare delivery, and advanced digital infrastructure supporting longitudinal monitoring. Many provincial hospitals utilize AI-powered platforms for real-time tracking of anthropometrics, menstrual logs, and home glucose monitoring, enabling proactive intervention. Traditional Chinese Medicine (TCM) is frequently incorporated as complementary therapy—e.g., acupuncture for menstrual regulation or herbal formulas like Gui Zhi Fu Ling Wan for blood stasis patterns—under dual-endocrinologist/TCM physician supervision, with growing evidence for synergistic effects on insulin sensitivity and inflammation. Furthermore, China’s centralized pharmaceutical procurement system ensures affordability of essential agents (metformin, COCs, spironolactone), and national insurance coverage extends to fertility-related diagnostics and letrozole for ovulation induction.

Recovery and long-term follow-up are integral to sustainable outcomes. Patients are advised to maintain weight stability post-intervention, with quarterly endocrinology visits during active treatment and annual comprehensive assessments thereafter—including fasting glucose, HbA1c, lipid profile, liver enzymes, blood pressure, and pelvic ultrasound if clinically indicated. Endometrial surveillance via transvaginal ultrasound or saline infusion sonography is recommended for women with prolonged amenorrhea (>6 months) or abnormal uterine bleeding. Psychological well-being must be routinely assessed; referral to clinical psychology services is standard in major Chinese centers. Breastfeeding is encouraged postpartum, as it confers metabolic benefits and may delay PCOS symptom recurrence. Adolescents require specialized transition care from pediatric to adult endocrinology services, with emphasis on education about self-management, contraception, and future fertility planning. Finally, all women with PCOS should receive cardiovascular risk counseling, including smoking cessation, sodium restriction, and aspirin consideration only in high-risk subgroups per ASCVD risk calculators validated in Asian populations. With consistent, patient-centered care, most individuals achieve symptom control, metabolic stabilization, and reproductive autonomy—underscoring PCOS not as a static diagnosis but a lifelong, modifiable endocrine trajectory.